What the FDA labels say about taking them together
Disopyramide and repaglinide
Repaglinide's FDA label of May 2, 2025 names disopyramide in its drug interactions section; the disopyramide label PlainMeds reads does not name repaglinide. The repaglinide label: “… Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline …”
Check it at the source: the disopyramide FDA label on DailyMed (effective August 24, 2026, Pfizer Laboratories Div Pfizer Inc); the repaglinide FDA label on DailyMed (effective May 2, 2025, Chartwell RX, LLC).
What does the disopyramide label say about repaglinide?
Disopyramide's label (effective August 24, 2026) does not name repaglinide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norpace), Pfizer Laboratories Div Pfizer Inc, effective August 24, 2026 (SPL set e2aa1642-d262-4520-bc6a-9fd3ad795677), via openFDA; the full label on DailyMed
What does the repaglinide label say about disopyramide?
Repaglinide label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Intervention: Repaglinide tablets dose reductions and increased frequency of glucose monitoring may be required when co-administered. Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.
Source: FDA drug label (Repaglinide), Chartwell RX, LLC, effective May 2, 2025 (SPL set cb995e92-295e-4638-a064-978211f5afe1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Disopyramide | Repaglinide | |
|---|---|---|
| Labeled for | n/a | Type 2 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.801 per capsule 100 mg capsule | $0.0987 per tablet 1 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once